10.22.2019 - By Sean P. Kane, PharmD; Khyati Patel, PharmD
In this episode, we discuss the newly published DAPA-HF trial, which studied dapagliflozin (a drug for diabetes) among patients who had heart failure with reduced ejection fraction (HFrEF) many of which did NOT have a history of diabetes.